TS
Therapeutic Areas
Immuneering Pipeline
| Drug | Indication | Phase |
|---|---|---|
| IMM-1-104 (implied lead) | Advanced solid tumors with MAPK pathway mutations (e.g., KRAS, NRAS, BRAF) | Phase 1/2a |
| Preclinical Programs | MAPK-driven cancers | Preclinical |
Leadership Team at Immuneering
BZ
Ben Zeskind
Co-Founder, President, Chief Executive Officer, Director
MB
Michael Bookman
Chief Legal Officer, Secretary
H“
Harold “E.B.” Brakewood
Chief Business Officer
BH
Brett Hall
Chief Scientific Officer
BC
Bob Carpenter
Co-founder, Chair Emeritus, Board Member
PF
Peter Feinberg
Board Member
CA
Christian Alaia
Senior Director, Financial Planning & Analysis
NA
Naseem Alkaabi
Senior Research Associate
DA
Damaris Arcila
Senior Accountant
HA
Hemalatha Athawale
Senior Research Associate